A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J. Short, Hagop Kantarjian, Elias Jabbour et al.|Blood Advances|2024Cited by 35
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lü, Shucai Zhang, Shundong Cang et al.|Journal of Thoracic Oncology|2022Cited by 25